These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 1975166)

  • 1. The clinical use of somatostatin analogues in the treatment of cancer.
    Lamberts SW; Krenning EP; Klijn JG; Reubi JC
    Baillieres Clin Endocrinol Metab; 1990 Mar; 4(1):29-49. PubMed ID: 1975166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A guide to the clinical use of the somatostatin analogue SMS 201-995 (Sandostatin).
    Lamberts SW
    Acta Endocrinol Suppl (Copenh); 1987; 286():54-66. PubMed ID: 2892338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
    Öberg K; Lamberts SW
    Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future medical prospects for Sandostatin.
    Harris AG
    Z Gastroenterol; 1990 Sep; 28 Suppl 2():55-60. PubMed ID: 1980778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin receptor imaging with 123I-Tyr3-Octreotide.
    Lamberts SW; Reubi JC; Bakker WH; Krenning EP
    Z Gastroenterol; 1990 Sep; 28 Suppl 2():20-1. PubMed ID: 1980773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with Sandostatin and in vivo localization of tumors with radiolabeled somatostatin analogs.
    Lamberts SW; Bakker WH; Reubi JC; Krenning EP
    Metabolism; 1990 Sep; 39(9 Suppl 2):152-5. PubMed ID: 2169572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-pituitary actions of somatostatin. A review on the therapeutic role of SMS 201-995 (sandostatin).
    Lamberts SW
    Acta Endocrinol Suppl (Copenh); 1986; 276():41-55. PubMed ID: 2875590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future medical prospects for Sandostatin.
    Harris AG
    Metabolism; 1990 Sep; 39(9 Suppl 2):180-5. PubMed ID: 2205787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas.
    Reubi JC; Kvols LK; Waser B; Nagorney DM; Heitz PU; Charboneau JW; Reading CC; Moertel C
    Cancer Res; 1990 Sep; 50(18):5969-77. PubMed ID: 2168286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
    Oberg K
    Ann Oncol; 2001; 12 Suppl 2():S111-4. PubMed ID: 11762335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin receptors: clinical implications for endocrinology and oncology.
    Lamberts SW; de Herder WW; van Koetsveld PM; Koper JW; van der Lely AJ; Visser-Wisselaar HA; Hofland LJ
    Ciba Found Symp; 1995; 190():222-36; discussion 236-9. PubMed ID: 7587649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues.
    Wahid ST; Marbach P; Stolz B; Miller M; James RA; Ball SG
    Eur J Endocrinol; 2002 Mar; 146(3):295-302. PubMed ID: 11888834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.
    Modlin IM; Pavel M; Kidd M; Gustafsson BI
    Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of somatostatin receptors in normal and tumor tissue.
    Reubi JC; Kvols L; Krenning E; Lamberts SW
    Metabolism; 1990 Sep; 39(9 Suppl 2):78-81. PubMed ID: 2169575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.
    Biermasz NR; van den Oever NC; Frölich M; Arias AM; Smit JW; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2003 Mar; 58(3):288-95. PubMed ID: 12608933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
    Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
    Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours.
    Chanson P; Timsit J; Harris AG
    Clin Pharmacokinet; 1993 Nov; 25(5):375-91. PubMed ID: 8287633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
    Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
    Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Somatostatin analogues in treatment of gastrointestinal and pancreatic neuroendocrine tumors].
    Simonenko VB; Dulin PA; Makanin MA
    Klin Med (Mosk); 2006; 84(4):4-8. PubMed ID: 16755846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.
    Klijn JG; Hoff AM; Planting AS; Verweij J; Kok T; Lamberts SW; Portengen H; Foekens JA
    Br J Cancer; 1990 Oct; 62(4):627-30. PubMed ID: 1977468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.